tradingkey.logo


tradingkey.logo


Boston Scientific Corp

BSX
70.170USD
+0.390+0.56%
āļ›āļīāļ” 03/26, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
100.64BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
35.85P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Boston Scientific Corp āļšāļĢāļīāļĐāļąāļ—

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

āļ‚āđ‰āļ­āļĄāļđāļĨ Boston Scientific Corp


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™BSX
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Boston Scientific Corp
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļMay 19, 1992
āļ‹āļĩāļ­āļĩāđ‚āļ­Mahoney (Michael F)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™53000
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“May 19
āļ—āļĩāđˆāļ­āļĒāļđāđˆ300 Boston Scientific Way
āđ€āļĄāļ·āļ­āļ‡MARLBOROUGH
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX NASDAQ Basic NYSE
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ01752-1234
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ15086834000
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.bostonscientific.com/en-US/Home.html
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™BSX
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļMay 19, 1992
āļ‹āļĩāļ­āļĩāđ‚āļ­Mahoney (Michael F)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Boston Scientific Corp


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.86M
+0.66%
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
54.72K
--
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
54.24K
--
Mr. David S. (Dave) Wichmann
Mr. David S. (Dave) Wichmann
Independent Director
Independent Director
41.58K
--
Mr. Jonathan R. Monson
Mr. Jonathan R. Monson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
37.99K
--
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
24.13K
--
Mr. David C. Habiger
Mr. David C. Habiger
Independent Director
Independent Director
5.63K
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
2.08K
--
Mr. Joseph M. Fitzgerald
Mr. Joseph M. Fitzgerald
Executive Vice President, Group President - Cardiology
Executive Vice President, Group President - Cardiology
--
--
Mr. Edward J. Ludwig
Mr. Edward J. Ludwig
Lead Independent Director
Lead Independent Director
--
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.86M
+0.66%
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
54.72K
--
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
54.24K
--
Mr. David S. (Dave) Wichmann
Mr. David S. (Dave) Wichmann
Independent Director
Independent Director
41.58K
--
Mr. Jonathan R. Monson
Mr. Jonathan R. Monson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
37.99K
--
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
24.13K
--

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Endoscopy
747.00M
14.75%
Peripheral Interventions
702.00M
13.86%
Urology
682.00M
13.46%
Electrophysiology
607.00M
11.98%
Watchman
470.00M
9.28%
āļ­āļ·āđˆāļ™ āđ†
1.86B
36.66%
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
United States
3.29B
65.03%
Asia Pacific
802.00M
15.83%
EMEA (Europe, Middle East and Africa)
793.00M
15.66%
Latin America and Canada
175.00M
3.46%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Endoscopy
747.00M
14.75%
Peripheral Interventions
702.00M
13.86%
Urology
682.00M
13.46%
Electrophysiology
607.00M
11.98%
Watchman
470.00M
9.28%
āļ­āļ·āđˆāļ™ āđ†
1.86B
36.66%

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļĻāļļāļāļĢāđŒāļ—āļĩāđˆ 20 āļ.āļž.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļĻāļļāļāļĢāđŒāļ—āļĩāđˆ 20 āļ.āļž.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
The Vanguard Group, Inc.
9.35%
Fidelity Management & Research Company LLC
5.85%
BlackRock Institutional Trust Company, N.A.
5.40%
State Street Investment Management (US)
4.43%
Geode Capital Management, L.L.C.
2.18%
āļ­āļ·āđˆāļ™ āđ†
72.79%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
The Vanguard Group, Inc.
9.35%
Fidelity Management & Research Company LLC
5.85%
BlackRock Institutional Trust Company, N.A.
5.40%
State Street Investment Management (US)
4.43%
Geode Capital Management, L.L.C.
2.18%
āļ­āļ·āđˆāļ™ āđ†
72.79%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
51.42%
Investment Advisor/Hedge Fund
27.37%
Hedge Fund
6.13%
Pension Fund
3.12%
Research Firm
2.80%
Bank and Trust
1.85%
Sovereign Wealth Fund
1.83%
Family Office
0.29%
Private Equity
0.23%
āļ­āļ·āđˆāļ™ āđ†
4.94%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 8 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 8 āļ˜.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q4
2858
1.40B
94.34%
-402.85K
2025Q3
2905
1.40B
94.56%
+9.92M
2025Q2
2818
1.39B
94.08%
+7.87M
2025Q1
2724
1.38B
93.98%
-8.23M
2024Q4
2559
1.38B
93.68%
+12.79M
2024Q3
2401
1.36B
94.13%
-3.01M
2024Q2
2325
1.37B
94.20%
+2.64M
2024Q1
2212
1.37B
95.15%
-32.63M
2023Q4
2153
1.38B
96.34%
-8.17M
2023Q3
2083
1.39B
95.41%
+17.41M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
The Vanguard Group, Inc.
137.57M
9.28%
+1.09M
+0.80%
Sep 30, 2025
Fidelity Management & Research Company LLC
90.62M
6.11%
-8.85M
-8.90%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
79.60M
5.37%
+1.41M
+1.81%
Sep 30, 2025
State Street Investment Management (US)
64.93M
4.38%
-266.30K
-0.41%
Sep 30, 2025
Geode Capital Management, L.L.C.
32.69M
2.21%
+265.55K
+0.82%
Sep 30, 2025
PRIMECAP Management Company
33.10M
2.23%
-1.56M
-4.50%
Sep 30, 2025
Capital World Investors
26.65M
1.8%
-1.88M
-6.58%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
19.46M
1.31%
-275.11K
-1.39%
Jun 30, 2025
The Bollard Group, LLC
19.73M
1.33%
-345.87K
-1.72%
Sep 30, 2025
BlackRock Investment Management (UK) Ltd.
17.39M
1.17%
-975.38K
-5.31%
Sep 30, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 1 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 1 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
iShares U.S. Medical Devices ETF
12.15%
Goldman Sachs Future Health Care Equity ETF
8.33%
Invesco Dorsey Wright Healthcare Momentum ETF
3.87%
Tema Heart & Health ETF
3.66%
First Trust Bloomberg R&D Leaders ETF
3.14%
Parnassus Core Select ETF
3.1%
WisdomTree US AI Enhanced Value Fund
3.1%
Health Care Select Sector SPDR Fund
3.06%
Global X Aging Population ETF
2.99%
Proshares Ultra Health Care
2.95%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
iShares U.S. Medical Devices ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™12.15%
Goldman Sachs Future Health Care Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™8.33%
Invesco Dorsey Wright Healthcare Momentum ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.87%
Tema Heart & Health ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.66%
First Trust Bloomberg R&D Leaders ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.14%
Parnassus Core Select ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.1%
WisdomTree US AI Enhanced Value Fund
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.1%
Health Care Select Sector SPDR Fund
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.06%
Global X Aging Population ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.99%
Proshares Ultra Health Care
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.95%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™